4-(2,2,2-三氟乙酰)苯甲酸 | 58808-59-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 4-(2,2,2-三氟乙酰)苯甲酸
• 中文别名: 4-(三氟乙酰基)苯甲酸
• 英文名称: 4-(trifluoroacetyl)benzoic acid
• 英文别名: 4-(2,2,2-trifluoroacetyl)benzoic acid；4-(trifluoroacetoxy)benzoic acid；4-trifluoroacetylbenzoic acid；p-trifluoroacetylbenzoic acid；4-(2,2,2-trifluoro-acetyl)-benzoic acid
• CAS: 58808-59-6
• 化学式: C₉H₅F₃O₃
• mdl: MFCD00052340
• 分子量: 218.132
• InChiKey: WLTZCRCZDLLXQP-UHFFFAOYSA-N

物化性质

• 熔点：
  178 °C
• 沸点：
  313.5±42.0 °C(Predicted)
• 密度：
  1.455±0.06 g/cm3(Predicted)
• 稳定性/保质期：
  避免接触氧化物

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.111
• 拓扑面积：
  54.4
• 氢给体数：
  1
• 氢受体数：
  6

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 危险类别码：
  R36/37/38
• 海关编码：
  2918300090
• 安全说明：
  S26,S36
• WGK Germany：
  3
• 储存条件：
  在密封的贮藏器中存放，并置于阴凉、干燥处。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
4-(Trifluoroacetyl)benzoic acid
Product Name:
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
4-(Trifluoroacetyl)benzoic acid
Ingredient name:
CAS number: 58808-59-6

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C9H5F3O3
Molecular weight: 218.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen fluoride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-(2,2,2-三氟乙酰)苯甲酸 在 吡啶 、 lithium hydroxide monohydrate 、 硫酸 、 盐酸羟胺 、 氨 、 水 、 三乙胺 作用下， 以 四氢呋喃 、 乙醚 、 二氯甲烷 为溶剂， 反应 50.0h， 生成 4-(3-(trifluoromethyl)diaziridin-3-yl)benzoic acid
  参考文献：
  名称：

  作为 SIRT5 抑制剂的新 ε-N-硫代戊二酰赖氨酸衍生物：化学合成、动力学和晶体学研究

  摘要：

  SIRT5 与各种生理过程和人类疾病（包括癌症）有关。仍然需要开发新的高效选择性 SIRT5 抑制剂来研究疾病相关机制和治疗潜力。我们在这里报告了新的 ε- N -thioglutaryllysine 衍生物，它们是根据 SIRT5 催化的脱酰反应设计的。这些 ε- N-硫代戊二酰赖氨酸衍生物显示出有效的 SIRT5 抑制作用，其中潜在的光交联衍生物8对 SIRT5 具有 120 nM 的 IC 50值，对 SIRT1-3 和 SIRT6 具有低抑制作用。酶动力学分析表明，ε- N-thioglutaryllysine 衍生物通过赖氨酸底物竞争方式抑制 SIRT5。共晶体分析表明，8通过与 SIRT5 特异性残基形成氢键和静电相互作用，结合以占据赖氨酸-底物结合位点，并且可能与 NAD +反应并形成稳定的硫代中间体。观察到化合物8与 SIRT5 的光交联概率低，这可能是由于在 SIRT5:

  DOI：

  10.1016/j.bioorg.2023.106487
• 作为产物：
  描述：

  4-(三氟乙酰基)甲苯 在 Jones oxidation 作用下， 以49%的产率得到4-(2,2,2-三氟乙酰)苯甲酸
  参考文献：
  名称：

  贝克酵母还原法立体合成高光学纯度的对位取代三氟甲基苄醇衍生物

  摘要：

  通过在对位引入一些官能团可以提高面包师酵母还原对位取代的三氟乙酰苯衍生物的对映选择性，从而以高化学和光学收率得到相应的（R）-三氟甲基取代的苄醇。所获得的旋光性醇易于通过重结晶转化成旋光纯净的形式。

  DOI：

  10.1016/s0957-4166(00)80234-7

文献信息

• [EN] TETRAHYDRO-BENZODIAZEPINONES<br/>[FR] TÉTRAHYDRO-BENZODIAZÉPINONES
  申请人：HOFFMANN LA ROCHE

  公开号：WO2015071393A1

  公开（公告）日：2015-05-21

  Disclosed are compounds of Formula I, or pharmaceutically acceptable salts thereof, wherein W, X, Y, Z, R1, R2, R3, R4 and R5 are as described in this application, and methods of using said compounds in the treatment of cancer.

  本申请公开了具有I式化合物或其药用可接受盐的化合物，其中W、X、Y、Z、R1、R2、R3、R4和R5如本申请所述，并且使用所述化合物治疗癌症的方法。
• Cholanic acid ring based 4-(trifluoroacetyl)phenyl derivatives, process for preparation and use thereof
  申请人：Pyun Hyung Jung

  公开号：US06177417B1

  公开（公告）日：2001-01-23

  The present invention relates to a cholanic acid ring based 4-(trifluoroacetyl)phenyl derivatives of the following formula 1, process for preparation and use thereof. The cholanic acid ring based 4-(trifluoroacetyl)phenyl derivatives of the present invention may be used as a host material in the host-guest chemistry, in detail as a material for ion sensors, optical sensors, gas sensors, biosensors, chromatographies, photostimulated ion-binding resins, ion exchange resins and organic reactions. (In the above formula 1, R, R1, R2, R3 and n are defined in the specifications).

  本发明涉及基于胆酸环的4-(三氟乙酰基)苯衍生物的以下化学式1，其制备方法和用途。本发明的基于胆酸环的4-(三氟乙酰基)苯衍生物可用作主客体化学中的主体材料，具体而言可用作离子传感器、光学传感器、气体传感器、生物传感器、色谱、光刺激离子结合树脂、离子交换树脂和有机反应的材料。 （在上述化学式1中，R、R1、R2、R3和n的定义详见说明书）。
• Substituted 1,2,3,4-tetrahydronaphthalene derivatives
  申请人：Astra Aktiebolag

  公开号：US06124283A1

  公开（公告）日：2000-09-26

  New piperidinyl- or piperazinyl-substituted-1,2,3,4-tetrahydronaphthalene derivatives having the formula ##STR1## wherein X is N or CH; Y is NR.sub.2 CH.sub.2, CH.sub.2 --NR.sub.2, NR.sub.2 --CO, CO--NR.sub.2 or NR.sub.2 SO.sub.2 ; R.sub.1 is H, C.sub.1 -C.sub.6 alkyl or C.sub.3 -C.sub.6 cycloalkyl; R.sub.3 is C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl or (CH.sub.2).sub.n -aryl, where aryl is phenyl or a heteroaromatic ring containing one or two heteroatoms selected from N, O and S and which may be mono- or di-substituted; n is 0-4; as (R)-enantiomer, (S)-enantiomer or a racemate in the form of the free base or a pharmaceutically acceptable salt or hydrate thereof; a pharmaceutical formulation containing the compounds, use of the compounds in the treatment of 5-hydroxytryptamine mediated disorders, processes for the preparation of the compounds and intermediates for the preparation of the compounds.

  新的哌啶基或哌嗪基取代的1,2,3,4-四氢萘衍生物具有以下结构式：##STR1## 其中X为N或CH；Y为NR.sub.2 CH.sub.2，CH.sub.2--NR.sub.2，NR.sub.2--CO，CO--NR.sub.2或NR.sub.2 SO.sub.2；R.sub.1为H，C.sub.1-C.sub.6烷基或C.sub.3-C.sub.6环烷基；R.sub.3为C.sub.1-C.sub.6烷基，C.sub.3-C.sub.6环烷基或(CH.sub.2).sub.n-芳基，其中芳基为苯基或含有N、O和S中的一个或两个杂原子的杂芳环，可以是单取代或双取代；n为0-4；作为(R)-对映体，(S)-对映体或自由碱形式或其药学上可接受的盐或水合物的混合物；含有这些化合物的药物配方，这些化合物在治疗5-羟色胺介导的疾病中的用途，制备这些化合物的方法以及制备这些化合物的中间体。
• [EN] ALIPHATIC PROLINAMIDE DERIVATIVES<br/>[FR] DÉRIVÉS DE PROLINAMIDE ALIPHATIQUE
  申请人：INCEPTION 4 INC

  公开号：WO2017222917A1

  公开（公告）日：2017-12-28

  This invention is directed to novel aliphatic prolinamide derivatives of Formula I, and pharmaceutically acceptable salts, solvates, solvates of the salt and prodrugs thereof, useful in the prevention (e.g., delaying the onset of or reducing the risk of developing) and treatment (e.g., controlling, alleviating, or slowing the progression of) of age-related macular degeneration (AMD) and related diseases of the eye. These diseases include dry-AMD, wet-AMD, geographic atrophy, diabetic retinopathy, retinopathy of prematurity, polypoidal choroidal vasculopathy, and degeneration of retinal or photoreceptor cells. The invention disclosed herein is further directed to methods of prevention, slowing the progress of, and treatment of dry-AMD, wet-AMD, and geographic atrophy, diabetic retinopathy, retinopathy of prematurity, polypoidal choroidal vasculopathy, and degeneration of retinal or photoreceptor cells, comprising: administration of a therapeutically effective amount of compound of the invention. The compounds of the invention are inhibitors of HTRAl. Thus, the compounds of the invention are useful in the prevention and treatment of a wide range of diseases mediated (in whole or in part) by HTRAl. The compounds of the invention are also useful for inhibiting HTRAl protease activity in an eye or locus of an arthritis or related condition.

  这项发明涉及一种新型的脂肪族脯氨酰胺衍生物，其化学式为I，并且包括药学上可接受的盐、溶剂化合物、盐的溶剂化合物和其前药，用于预防（例如，延缓或减少发展风险）和治疗（例如，控制、缓解或减缓进展）与眼睛相关的年龄相关性黄斑变性（AMD）及相关眼部疾病。这些疾病包括干性AMD、湿性AMD、地理性萎缩、糖尿病视网膜病变、早产儿视网膜病变、多发性脉络膜血管病变以及视网膜或光感受器细胞的退化。本公开的发明还涉及预防、减缓进展和治疗干性AMD、湿性AMD和地理性萎缩、糖尿病视网膜病变、早产儿视网膜病变、多发性脉络膜血管病变以及视网膜或光感受器细胞的方法，包括：给予所述发明化合物的治疗有效量。本发明的化合物是HTRAl的抑制剂。因此，本发明的化合物在预防和治疗一系列（全部或部分）由HTRAl介导的疾病中具有用途。本发明的化合物还可用于抑制眼部或关节炎或相关疾病部位的HTRAl蛋白酶活性。
• Enantioselective Palladium-Catalyzed [3+2] Cycloaddition of Trimethylenemethane and Fluorinated Ketones
  作者：Barry M. Trost、Guillaume Mata

  DOI：10.1002/anie.201807308

  日期：2018.9.17

  undergoes palladium‐catalyzed [3+2] cycloadditions with fluorinated ketones to generate tetrasubstituted trifluoromethylated centers in high enantioselectivity under mild conditions. The generation of the palladium–TMM complex was achieved by a self‐deprotonation strategy, which shows remarkable improvements in regiocontrol, efficiency, and atom economy of asymmetric [3+2] cycloadditions. Moreover, the

  腈取代的三亚甲基甲烷（TMM）供体与氟化酮进行钯催化的[3 + 2]环加成反应，在温和条件下以高对映选择性生成四取代的三氟甲基化中心。钯-TMM络合物的生成是通过自去质子化策略实现的，该策略显示了非对称[3 + 2]环加成反应的区域控制，效率和原子经济性的显着改善。此外，腈基的多功能性可直接获得各种合成有用的中间体，包括酰胺，醛和酯。发达的反应条件允许以优异的区域选择性和对映体选择性合成各种芳族，杂芳族和脂族氟化二氢呋喃。

表征谱图